Search Results

You are looking at 111 - 120 of 614 items for :

  • "surveillance" x
Clear All
Full access

Surveillance Monitoring More Stringent in Updated NCCN Guidelines for Prostate Cancer Active surveillance or immediate treatment? The question that many men with prostate cancer and their clinicians struggle with continues to be a focus in the updated NCCN

Full access

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld and Darren R. Feldman

testicle, who choose an active surveillance management strategy. Active surveillance implies careful monitoring of patients, with treatment reserved exclusively for those who experience disease relapse. Patients with stage I disease must have no

Full access

Hideki Furuya and Charles J. Rosser

bladder cancer are subpar. Briefly, the FDA has approved 4 urine-based assays for bladder cancer detection (UroVysion for initial evaluation and tumor surveillance, ImmunoCyt for tumor surveillance, BTA stat for initial evaluation and tumor surveillance

Full access

Stacy Loeb and William J. Catalona

. Surveillance, Epidemiology, and End Results (SEER) Program . SEER * Stat Database: Incidence - SEER 17 Regs Public-Use, Nov 2005 Sub (1973-2003 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April

Full access

Huong T. Le-Petross

resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer . J Clin Oncol 2001 ; 19 : 3524 – 3531 . 12. Stoutjesdijk MJ Boetes C Jager GJ . Magnetic resonance imaging and mammography in

Full access

Philip W. Kantoff and James L. Mohler

overall survival benefit in metastatic castration-resistant prostate cancer (mCRPC). Treatment Versus Active Surveillance James L. Mohler, MD, Chair of the NCCN Panel on Prostate Cancer, discussed 4 areas of controversy in prostate cancer in

Full access

Nishant Patel, Adam C. Yopp and Amit G. Singal

rates near 70% with resection or liver transplantation, whereas those with advanced HCC have a median survival of less than 1 year. 2 Surveillance at 6-month intervals is recommended in patients with cirrhosis and is associated with improved early

Full access

En Cheng, Peiyin Hung and Shi-Yi Wang

of HCC, it is critical to investigate geographic variations in HCC curative treatments and their associations with survival among HCC patients. Methods: Analyzing the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we

Full access

Joseph J. Fantony and Brant A. Inman

Bladder cancer is the second most common malignancy of the genitourinary tract and fifth most common malignancy overall in the United States. 1 The current standard for diagnosis and surveillance of bladder cancer includes a combination of

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

experience relapse. To prevent relapse in patients with stages IA and IB pure seminoma, the standard management options after initial orchiectomy include active surveillance, RT, or chemotherapy with 1 or 2 cycles of carboplatin. The disease-specific survival